Investigative ophthalmology & visual science, vol.48, no.4, pp.1773-81, 2007 (SCI-Expanded)
PURPOSE. To evaluate the preclinical safety of intravitreal bevacizumab, which is a full-length humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), in rabbit eves over a short-term period.